Recruiting Psoriasis Studies in Chandler
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-ter...
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) wo...
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who ...
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response ...
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammat...
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overw...
About Psoriasis Clinical Trials in Chandler
Psoriasis is a chronic autoimmune skin condition affecting over 8 million Americans, causing cells to build up rapidly on the surface and forming red, scaly patches that can be itchy and painful. Plaque psoriasis accounts for about 80-90% of cases. While current treatments include topical therapies, phototherapy, and biologics like TNF inhibitors (adalimumab, etanercept) and IL-17/IL-23 inhibitors (secukinumab, guselkumab), clinical trials are testing next-generation oral treatments, TYK2 inhibitors, and combination approaches that may offer longer remission periods with fewer side effects. Patients with moderate-to-severe psoriasis who have not responded adequately to existing therapies are often sought for clinical trial enrollment.
There are currently 6 psoriasis clinical trials recruiting participants in Chandler, ARIZONA. These studies are seeking a combined 4,933 participants. Research is being sponsored by Alumis Inc, Takeda, MoonLake Immunotherapeutics AG and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Psoriasis Clinical Trials in Chandler — FAQ
Are there psoriasis clinical trials in Chandler?
Yes, there are 6 psoriasis clinical trials currently recruiting in Chandler, ARIZONA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Chandler?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chandler research site will contact you about next steps.
Are clinical trials in Chandler free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chandler studies also compensate for your time and travel.
What psoriasis treatments are being tested?
The 6 active trials in Chandler are testing new therapies including novel drugs, biologics, and treatment approaches for psoriasis.
Data updated March 2, 2026 from ClinicalTrials.gov